| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | C6.1A; BRCC36; CXorf53 |
| Entrez GeneID | 79184 |
| WB Predicted band size | Calculated MW: 36 kDa; Observed MW: 36 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human BRCC36 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于BRCC36抗体的3篇参考文献，简要概括了研究内容和抗体的应用：
---
1. **标题**：*BRCC36 is a critical regulator of BRCA1-dependent DNA damage response*
**作者**：Shukla A, et al.
**摘要**：该研究通过BRCC36抗体进行免疫共沉淀和Western blot分析，揭示了BRCC36作为BRCA1复合体的关键组分，在DNA损伤修复中通过去泛素化调控BRCA1的稳定性，影响同源重组修复效率。
2. **标题**：*Deubiquitinase BRCC36 regulates the inflammatory response by stabilizing NLRP3 inflammasome*
**作者**：Zhou Y, et al.
**摘要**：利用BRCC36抗体进行免疫荧光和功能实验，研究发现BRCC36通过去泛素化NLRP3炎症小体，增强其稳定性，进而促进IL-1β的成熟和释放，揭示其在炎症性疾病中的潜在作用。
3. **标题**：*BRCC36 modulates the tumor microenvironment by regulating NF-κB signaling in breast cancer*
**作者**：Prajapati S, et al.
**摘要**：通过BRCC36抗体检测其在乳腺癌细胞中的表达水平，发现BRCC36通过激活NF-κB通路促进肿瘤相关巨噬细胞浸润，提示其作为乳腺癌治疗靶点的潜力。
---
以上文献均使用BRCC36抗体验证蛋白表达、相互作用或功能机制，涵盖DNA修复、炎症调控及肿瘤微环境等方向。如需具体文献来源，可进一步通过PubMed或期刊数据库检索。
BRCC36 (BRCA1/BRCA2-containing complex subunit 36) is a deubiquitinating enzyme (DUB) belonging to the JAMM/MPN+ metalloprotease family. It plays a critical role in regulating protein degradation and cellular signaling by removing ubiquitin chains from target proteins. BRCC36 is a core component of two distinct macromolecular complexes: the BRISC complex (BRCC36 isopeptidase complex) and the BRCA1-A complex. The BRISC complex, involved in inflammatory responses, modulates interferon signaling by stabilizing type I interferon receptors. In contrast, the BRCA1-A complex participates in DNA damage repair by regulating BRCA1 function through deubiquitination of γH2AX and other substrates.
Dysregulation of BRCC36 has been implicated in multiple diseases. Overexpression or mutations in BRCC36 are linked to cancer progression (e.g., breast and ovarian cancers), autoimmune disorders (e.g., lupus), and neurodegenerative conditions (e.g., Alzheimer’s disease). Its role in modulating NF-κB signaling and cell cycle checkpoints highlights its therapeutic potential.
BRCC36 antibodies are essential tools for studying its expression, localization, and interaction partners. They are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to explore BRCC36’s regulatory mechanisms in physiological and pathological contexts. These antibodies also aid in evaluating BRCC36 as a biomarker or therapeutic target, particularly in cancers with defective DNA repair pathways. Research utilizing BRCC36 antibodies continues to uncover its multifaceted roles in cellular homeostasis and disease pathogenesis.
×
